

Tue May 27 08:34:40 2003

us-09-

Sequence Match Listing

09/95 4456

RESULT 1
 AA432248
 DEFINITION AA432248 zwi8b02.s1 Soares-testis_NHT Homo sapiens cDNA clone IMAGE:782283
 ACCESSION AA432248
 VERSION AA432248.1
 KEYWORDS EST.
 ORGANISM human.

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 421)

Hillier,L., Allén,M., Bowles,L., Dubrook,T., Geisel,G., Jost,S.,

Kucaba,T., Lacy,M., Le,N., Lennon,G., Marra,M., Marin,J., Moore,B.

, Schellenberg,K., Steptoe,M., Tait,F., Theising,B., White,Y., Wylie

,T., Waterston,R. and Wilson,R.

Unpublished (1997)

TITLE Wash-Merck EST Project 1997

JOURNAL Unpublished

COMMENT Contact: Wilson RK

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@wuston.wustl.edu

This clone is available royalty-free through LBL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.

Seq primer: -41m13 fwd. ET from Amerham.

Source
 1. 421
 /organism="Homo sapiens"
 /ab_xref="taxon:9606"
 /clone="IMAGE:782283"
 /clone_lib="Soares-testis_NHT"
 /sex="male"
 /lab_host="DH10B"
 /note="Vector: pT73D-Pac (Pharmacia) with a modified
 polyclinker; Site 1: Not I; Site 2: Eco RI; 1st strand cDNA
 was prepared from mRNA obtained from Clontech Laboratories
 , Inc., and primed with a Not I - oligo(dt) primer [5',
 5'-TTTACCAATCTGAGTGCGAGGCGCCAAATTTCCTTTTTTTTTTTT 3'].
 Double-stranded cDNA was ligated to Eco RI adaptors
 (Pharmacia), digested with Not I and cloned into the Not I
 and Eco RI sites of the modified pT73 vector. Library
 went through one round of normalization to Cots⁵, and was
 constructed by Bent Soares and M. Fatima Bonaldo."

BASE COUNT	148 a	66 c	51 g	156 t
ORIGIN				
Query Match	100 %	Score 421;	DB 9;	Length 421;
Best Local Similarity	100 %;	Pred. No. 4	1e-58;	
Matches	421;	Conservative	0;	Mismatches 0;
				Indels 0;
				Gaps 0;
Qy	1	TTTTTTTTTTTCACTTTGAAATGCCTTAATAGGTGACAGCTGTTGAA	60	
Db	1	TTTTTTTTTTTTCATTTGAAATGCCTTAATAGGTGACAGCTGTTGAA	60	
Qy	61	AATGTAAGAATACATACAAATCTTAATACAAAGATAATTAAAGCATT	120	
Db	61	AATGTAAGAATACATACAAATCTTAATACAAAGATAATTAAAGCATT	120	
Qy	121	TTTTTAACTGCACTTGTCTAACAGTACACTTTTCATGATTCAGTGAA	180	
Db	121	TTTTTAACTGCACTTGTCTAACAGTACACTTTTCATGATTCAGTGAA	180	
Qy	181	AATCGAAATACATACAAATCTTAATACAAAGATAATTAAAGCATT	240	
Db	181	AATCGAAATACATACAAATCTTAATACAAAGATAATTAAAGCATT	240	
Qy	241	TCCCCATATTAACAGTCATTTACAGTCACAGTCAGTCAGTCAGGCA	300	
Db	241	TCCCCATATTAACAGTCATTTACAGTCACAGTCAGTCAGTCAGGCA	300	
Qy	301	GTATATGAACTTACACTGTTACTAGCAGTACTGGCTCATGATGACCTG	360	
Db	301	GTATATGAACTTACACTGTTACTAGCAGTACTGGCTCATGATGACCTG	360	
Qy	361	GATGGGTTGCAATATAGACTAACTACTGATGAAACAAATGGATTTA	420	
Db	361	GATGGGTTGCAATATAGACTAACTACTGATGAAACAAATGGATTTA	420	
Qy	421	A 421		
Db	421	A 421		

RESULT 1

for seta 85

AB65541
ID AB65541 standard; DNA; 421 BP.

XX

AC AB65541;

XX

DT 15 MAY 2002 (first entry)

XX

DE Lung cancer related gene sequence SEQ ID NO:3878.

XX

KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;

KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;

KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;

KW gene; ds.

XX

OS Homo sapiens.

XX

PN WO200194629-A2.

XX

PD 13-DEC-2001.

XX

PR 30-MAY-2001; 2001WO-US10838.

XX

PR 05-JUN-2000; 2000US-209473P.

PR 05-JUN-2000; 2000US-209531P.

PR 18-SEP-2000; 2000US-231133P.

PR 18-SEP-2000; 2000US-231617P.

PR 20-SEP-2000; 2000US-231009P.

PR 20-SEP-2000; 2000US-234034P.

PR 20-SEP-2000; 2000US-234052P.

PR 22-SEP-2000; 2000US-231509P.

PR 22-SEP-2000; 2000US-234567P.

AB6554

- cont -

PR	25-SEP-2000; 2000US-234923P.	Db	1 TTTTTTTTTTTCATTTGAAATGCTTAATAGTGACACTGTGCAA
PR	25-SEP-2000; 2000US-235077P.	Qy	61 AATGTAAGATACATACTACAATCTTATACAAAGATAATTAAGAGATTTCTT
PR	25-SEP-2000; 2000US-235082P.	Db	61 AATGTAAGATACATACTACAATCTTATACAAAGATAATTAAGAGATTTCTT
PR	25-SEP-2000; 2000US-235280P.	Qy	120
PR	26-SEP-2000; 2000US-235637P.	Db	120
PR	27-SEP-2000; 2000US-235638P.	Qy	121 TTTTAATCTGCACTTGTGCTACACGTCATCTTTCATGATTGAGTGACAG
PR	27-SEP-2000; 2000US-235711P.	Db	121 TTTTAATCTGCACTTGTGCTACACGTCATCTTTCATGATTGAGTGACAG
PR	27-SEP-2000; 2000US-235720P.	Qy	180
PR	27-SEP-2000; 2000US-235840P.	Db	180
PR	28-SEP-2000; 2000US-235863P.	Qy	181 AATCGAGTAACGATTTACAGCTTACAGTCAGTTGAGGACACCTAATCTT
PR	28-SEP-2000; 2000US-236028P.	Db	181
PR	28-SEP-2000; 2000US-236032P.	Qy	181 RATCCAGTAATCATTTACAGCTACAGTCAGTTGAGGACACCTAATCTT
PR	28-SEP-2000; 2000US-236034P.	Db	240
PR	28-SEP-2000; 2000US-236109P.	Qy	241 TCCCCATTAACAGAGCATTTACACAACCTGATAACTATTGACATAAT
PR	29-SEP-2000; 2000US-236111P.	Db	300
PR	29-SEP-2000; 2000US-236842P.	Qy	301 GTATGTRAACTTACACCTGACTGAACTAGCACTGTTGATCAGCACCTG
PR	29-SEP-2000; 2000US-236891P.	Db	360
PR	02-OCT-2000; 2000US-237172P.	Qy	301 GTATGTRAACTTACACCTGACTGAACTAGCACTGTTGATCAGCACCTG
PR	02-OCT-2000; 2000US-237173P.	Db	360
PR	02-OCT-2000; 2000US-237218P.	Qy	361 GATGGGTTGCTATATGAGACTAACTATACGATGAAACAATGGATTIA
PR	02-OCT-2000; 2000US-237294P.	Db	420
PR	02-OCT-2000; 2000US-237295P.	Qy	361 GATGGGTTGCTATATGAGACTAACTATACGATGAAACAATGGATTIA
PR	02-OCT-2000; 2000US-237316P.	Db	420
PR	03-OCT-2000; 2000US-237425P.	Qy	361 GATGGGTTGCTATATGAGACTAACTATACGATGAAACAATGGATTIA
PR	03-OCT-2000; 2000US-237588P.	Db	420
PR	03-OCT-2000; 2000US-237604P.	Qy	421 A 421
PR	03-OCT-2000; 2000US-237606P.	Db	421 A 421
PR	03-OCT-2000; 2000US-237608P.	Qy	421 A 421
PR	01-NOV-2000; 2000US-244867P.	Db	421 A 421
PR	01-NOV-2000; 2000US-245084P.	Qy	421 A 421
XX	(AVAL-) AVALON PHARM.	Db	421 A 421
PI	Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;	Db	421 A 421
PI	Soppet DR, Weaver Z;	Db	421 A 421
XX	DR WPI; 2002-188264/24.	Db	421 A 421
XX	Screening for anti-neoplastic agent involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, and determining a change in expression of a gene of a signature gene set	Db	421 A 421
PS	Claim 1; SEQ ID 3878; 44pp; English.	Db	421 A 421
XX	The present invention describes a method (M1) for screening for an anti-neoplastic agent. The method involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, determining a change in expression of at least one gene (I) of signature gene set, where (I) comprises a sequence (S) selected from 8447 sequences (given in ABI6664 to ABL7010), or is at least 95% identical to (S), where a change in expression is indicative of anti-neoplastic activity. (I) has cytostatic activity and can be used in gene therapy. M1 can be used for screening an anti-neoplastic agent, and can be used for producing a product which is the data collected with respect to the anti-neoplastic agent as a result of M1, and the data is sufficient to convey the chemical structure and/or properties of the agent. M1 can be used in the treatment of cancer such as colon, breast, stomach, lung, thyroid, oesophageal, ovarian, kidney, prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer, carcinoma, papillary carcinoma and Wilms' tumour.	Db	421 A 421
SQ	Sequence 421 BP; 148 A; 66 C; 51 G; 156 T; 0 other;	Db	421 A 421
Query Match	100.0%; Score 421; DB 24; Length 421;	Db	421 A 421
Best Local Similarity	100.0%; Pred. No. 4; 4e-74;	Db	421 A 421
Matches	421; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Db	421 A 421
1	TTTTTTTTTCAATTGAAATGCTTATAAGTGTGACACACTGTTTGCAA	Db	421 A 421
	Db	421 A 421	

ALIGNMENTS

for SEQ ID NO: 995

RESULT 1
ABL65685
ID ABL65685 standard; DNA: 327 BP.
XX
AC ABL65685;
XX
DT 15-MAY-2002 (first entry)
XX Lung cancer related gene sequence SEQ ID NO:4022.
DE Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; adenocarcinoma;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; ds.
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200194629 A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234599P.
PR 22-SEP-2000; 2000US-234567P.

LOCUS H1957 327 bp mRNA linear EST 29-JUN-1995
DEFINITION m14908-S1 Soesies infant brain INIB Homo sapiens cDNA clone
IMAGE:5513 3', mRNA sequence.
ACCESSION H1957
VERSION H1857.1 GI:885197
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE
 1 (bases 1 to 327)
AUTHORS
 Hillier, L., Clark, N., Dubroque, T., Elliston, K., Hawkins, M., Holman
 M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M., Parsons, J.,
 Rikitin, L., Rohlfing, T., Soares, M., Tan, F., Trevaskis, E., Waterston,
 R., Williamson, A., Wohlmann, P. and Wilson, R.
TITLE
 The WashU-Merck EST Project
JOURNAL
 Unpublished (1995)
COMMENT
 Contact: Wilson RK
 Washington University School of Medicine

Tel: 314 286 1800
Fax: 314 286 1810
Email: est@wattan.wustl.edu
High quality sequence steps: 305
Source: IMAGE Consortium, LBL
This clone is available royalty-free through LBL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.

FEATURES	Seq primer: Promega_21m13 High quality sequence stop: 305. Location/Qualifiers
source	I. 327
organism	"Homo sapiens"
/db_xref	"GDB:424323"
/db_xref	"taxon:9606"
/clone	"IMAGE:51513"
/clone_lib	"Soares infant brain 1NIB"
/sex	"female"
/dev_stage	"73 days post natal"
/lab_host	"DH10B (ampicillin resistant)"
/note	"Organ: Whole brain; Vector: Lafmid BA; Site_1: Not I; Site_2: Hind III; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5'-AACAGGAAAGATTCGGCGCCGAATTCTTTTTTTTTT 3']";
	double-stranded cDNA was ligated to Hind III adaptors (Pharmacia), digested with Not I and directionally cloned into the Not I and Hind III sites of the Lafmid BA vector. Library went through one round of normalization. Library constructed by Bent Soares and M.Fatima Bonaldo."
BASE COUNT	98 a 71 c 74 g 84 t
ORIGIN	

RESULTS	AM967462	LOCUS	AM967462	DEFINITION	EST37957 MAGE sequences, Magt Homo Sapiens cDNA, mRNA sequence.
				VERSION	AM967462_1 GI:8157299
		SOURCE		KEYWORDS	MAGE genes, Magt, Homo sapiens
		ORGANISM	Homo sapiens		
			Human		
		AUTHORS	I.B., Seeed, A.I., Abrenathy, K., Dharap, S., Gaspard, R., Gay, C., Holt	REFERENCE	Bukayrotta, Metzger, Pritsch, Catrachini, Molinide, Hmo.
		TITLE	Assessment of gene expression patterns in a model of colon tumor	COMMENT	Upregulated (2000)
		CONTACT	John Quackenbush	JOURLNAL	metastasis using a 19,200 element cDNA microarray
		PLATE	241		Cell
		EMAIL	301 838 0208		9712 Medical Research Institute for Genomic Research, Rockville, MD 20850, USA
		SEQ PRIMER	1..591	FEATURES	Best Local Similarity 99.7%, Score 376, DB 10, Length 591, Mismatches 0, Gaps 0, Indels 0, Gaps 0;
		SOURCE	1..591		Query Match
		BASE COUNT	204 a 95 c 96 g 196 t	ORIGIN	Best Local Similarity 99.7%, Score 376, DB 10, Length 591, Mismatches 0, Gaps 0, Indels 0, Gaps 0;
		/note=Vector: BluescriptSKm"			
		/db_xref="Taxon:9606"			
		/organism="Homo sapiens"			

ALIGNMENTS

RESULT 1
ABL65308
ID ABL65308 standard; DNA; 377 BP.

for SEQ ID NO: 1021

XX
AC

XX
DT

15-MAY-2002 (first entry)

XX DE Lung cancer related gene sequence SEQ ID NO:3645.

XX KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;

KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;

KW cytostatic; gene therapy; antineoplastic; Wilms' tumour; adenocarcinoma;

XX OS Homo sapiens.

XX PN WO200194629-A2.

XX PD 13-DRC-2001.

XX ^

XX PF 30-MAY-2001; 2001WO-US10838.

XX PR 05-JUN-2000; 2000US-209473P.

PR 05-JUN-2000; 2000US-209531P.

PR 18-SEP-2000; 2000US-233133P.

PR 18-SEP-2000; 2000US-233617P.

PR 20-SEP-2000; 2000US-234009P.

PR 20-SEP-2000; 2000US-234034P.

PR 22-SEP-2000; 2000US-234052P.

PR 22-SEP-2000; 2000US-234509P.

PR 22-SEP-2000; 2000US-234567P.

ARL 65308

- cont -

PR 25-SEP-2000; 2000US-234923P.
 PR 25-SEP-2000; 2000US-234924P.
 PR 25-SEP-2000; 2000US-235077P.
 PR 25-SEP-2000; 2000US-235082P.
 PR 25-SEP-2000; 2000US-235134P.
 PR 26-SEP-2000; 2000US-235637P.
 PR 26-SEP-2000; 2000US-235638P.
 PR 27-SEP-2000; 2000US-235711P.
 PR 27-SEP-2000; 2000US-235720P.
 PR 27-SEP-2000; 2000US-235840P.
 PR 28-SEP-2000; 2000US-235863P.
 PR 28-SEP-2000; 2000US-236032P.
 PR 28-SEP-2000; 2000US-236033P.
 PR 28-SEP-2000; 2000US-236034P.
 PR 28-SEP-2000; 2000US-236109P.
 PR 28-SEP-2000; 2000US-236111P.
 PR 29-SEP-2000; 2000US-236842P.
 PR 02-OCT-2000; 2000US-237172P.
 PR 02-OCT-2000; 2000US-237173P.
 PR 02-OCT-2000; 2000US-237278P.
 PR 02-OCT-2000; 2000US-237294P.
 PR 02-OCT-2000; 2000US-237316P.
 PR 03-OCT-2000; 2000US-237425P.
 PR 03-OCT-2000; 2000US-237598P.
 PR 03-OCT-2000; 2000US-237604P.
 PR 03-OCT-2000; 2000US-237608P.
 PR 01-NOV-2000; 2000US-244867P.
 PR 01-NOV-2000; 2000US-245084P.
 PR (AVAL-) AVALON PHARM.
 XX
 PI Young, PE, Augustus M.; Carter KC, Ebner R, Endress G, Horrigan S;
 PI Soppet DR, Weaver Z;
 XX
 WPI; 2002-188264/24.

PT Screening for anti-neoplastic agent involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, and determining a change in expression of a gene of a signature gene set. -

XX
 PS Claim 1: SEQ ID 3645; 44pp; English.

CC The present invention describes a method (M1) for screening for an anti-neoplastic agent. The method involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, determining a change in expression of at least one gene (1) of a signature gene set, where (1) comprises a sequence (S) selected from 8447 sequences (given in ABL61664 to ABL70110), or is at least 95% identical to (S), where a change in expression is indicative of anti-neoplastic activity. (1) has cytostatic activity and can be used in gene therapy. M1 can be used for screening an anti-neoplastic agent, and can be used for producing a product which is the data collected with respect to the anti-neoplastic agent as a result of M1, and the data is sufficient to convey the chemical structure and/or properties of the agent. M1 can be used in the treatment of cancer such as colon, breast, stomach, lung, thyroid, oesophageal, ovarian, prostate, or pancreatic cancer, adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer, infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilms' tumour.

SQ Sequence 377 BP; 143 A; 61 C; 56 G; 117 T; 0 other;

Query Match 100.0%; Score 377; DB 24; Length 377;
 Best Local Similarity 100.0%; Pred. No. 6. 9e-80;
 Matches 377; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAACATTAAGATTATTACAAACCATGATTATATTCCTTACACTTAAGGAATGA 60
 QY 61 TATGAACAACTTGTGGAGTAAATAGAAGGCAACTTGCTTCAGTTGTACCAAGTC 120
 Db 61 TATGAACAACTTGTGGAGTAAATAGAAGGCAACTTGCTTCAGTTGTACCAAGTC 120
 QY 121 ATCAASCGAACCGAAGAACCTGAGAACCTGTTTAAGAGGAGTCATTACTTGCCAGCA 180
 Db 121 ATCAAGCAGAACCTGAGAACCTGTTTAAGAGGAGTCATTACTTGCCAGCA 180
 QY 181 TTTCCTCCAATGAAAATAGTOATGCTTACCTGACACTTATAAATGTT 240
 Db 181 TTTCCTCCAATGAAAATAGTOATGCTTACCTGACACTTATAAATGTT 240
 QY 241 TATAAAAGCATTAGGCCATTTGATCTCACAGTTGGCTGAATTGGAAATCCACTGAT 300
 Db 241 TATAAAAGCATTAGGCCATTTGATCTCACAGTTGGCTGAATTGGAAATCCACTGAT 300
 QY 301 TAAAAATACTTACCCATACACATCCAAATTCAGTTAATAGTTAAAGTT 360
 Db 301 TAAAAATACTTACCCATACACATCCAAATTCAGTTAATAGTTAAAGTT 360
 QY 361 AGGCCCGGGCTATAG 377
 Db 361 AGGCCCGGGCTATAG 377

ALIGNMENTS

← SEQ ID NO 1612

RESULT 1
ABL64298
ID ABL64298 standard; DNA; 418 BP.
XX
AC ABL64298;
XX
DT 15-MAY-2002 (first entry)
XX
DE Stomach cancer related gene sequence SEQ ID NO:2635.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilms' tumour; adenocarcinoma;
XX
OS Homo sapiens.
XX
PN WO200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 07-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 20-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 22-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.

May 27 08:34:28 2003
AB64298 for

for
see 1062
— cont —

us-09-954-456-1062.rng

卷之三

WPI; 2002-188264/74.

determined agent to be tested for anti-neoplastic activity, and determining a change in expression of a gene of a signature gene set.

CC present invention describes a method (M1) for screening for an anti-neoplastic agent. The method involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, determining a change in expression of at least one gene (1) of a signature gene set, where (1) comprises a sequence (S) selected from 8447 sequences (given in ABL1664 to ABL0110), or is at least 95% identical to (S), where a change in expression is indicative of anti-neoplastic activity. (1) has cytostatic activity and can be used in gene therapy. M1 can be used for screening an anti-neoplastic agent, and can be used for producing a product which is the data collected with respect to the anti-neoplastic agent as a result of M1, and the data is sufficient to convey the chemical structure and/or properties of the agent. M1 can be used in the treatment of cancer such as colon, breast, stomach, lung, thyroid, oesophageal, ovarian, kidney, prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer, infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilms' tumour.

Query Match 99.8%; Score 417; DB 24; Length 418;

best local similarity 100.0%; pred. no. 6.1e-95; matches 418; conservative 0; mismatches 0; index

RESULTS

Tue May 27 08:34:28 2003

us-09-954

RESULT 1
 N71027
 LOCUS N71027
 DEFINITION za3503.s1 Soares fetal liver spleen 1NFLS linear EST 14-MAR-1996
 IMAGE:294533 3' similar to contains Alu repetitive element;, mRNA
 sequence.

ACCESSION N71027
 VERSION N71027.1 GI:1227607
 KEYWORDS EST.
 SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE 1 (bases 1 to 418)
 Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M., Holman

,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marr,M., Parsons,J.,

Riffin,L., Roilifing,T., Soares,M., Tan,F., Trevaskis,E., Waterston

,R., Williamson,A., Wohldmann,P. and Wilson,R.

Unpublished (1995)
 Contact: Wilson RK

Washington University School of Medicine

Tel: 314 286 1800
 Fax: 314 286 1810

Email: est@wustl.edu

This clone is available royalty-free through INFLN; contact the

IMAGE Consortium (<http://image.llnl.gov>) for further information.

Seq Primer: ml3 -40 forward

BASE COUNT
 ORIGIN
 Query Match 99.8%; Score 417; DB 14; Length 418;
 Best Local Similarity 100.0%; Pred. No. 5.5e-63;
 Matches 418; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 AACCTAGACAAAGAGAACCGTCAAGTATATAAAAAATCAGAACATGACAAATAG 60
 Qy 1 AACCTAGACAAAGAGAACCGTCAAGTATATAAAAAATCAGAACATGACAAATAG 60
 Db 1 AACCTAGACAAAGAGAACCGTCAAGTATATAAAAAATCAGAACATGACAAATAG 60
 Qy 61 GAGACTAATCCCTGATGCGRAAGATAATCATATAGTGCTTAAGAGGTAC 120
 Db 61 GAGACTAATCCCTGATGCGRAAGATAATCATATAGTGCTTAAGAGTAC 120
 Qy 121 TTAGATGAGCACAGTCACAGTGGCAACTGAGCACTAAACATGTTGACCTTATAACAT 180
 Db 121 TTAGATGAGCACAGTCACAGTGGCAACTGAGCACTAAACATGTTGACCTTATAACAT 180
 Qy 181 TCTTAGGGAAAAAATTTTAATTTGAAAAATATGGTTAGGCTAGTGCT 240
 Db 181 TCTTAGGGAAAAAATTTTAATTTGAAAAATATGGTTAGGCTAGTGCT 240
 Qy 241 CAGCTGTAAACCCAGCACATTAGGCCAACGGGGAGGCTGCCTGAGGTTAGGCT 300
 Db 241 CAGCTGTAAACCCAGCACATTAGGCCAACGGGGAGGCTGCCTGAGGTTAGGCT 300
 Qy 301 TTCAAGACCAGCTGGCAACATAGTGAGACCTGTCTACTAAACCTAAAGAT 360
 Db 301 TTCAAGACCAGCTGGCAACATAGTGAGACCTGTCTACTAAACCTAAAGAT 360
 Qy 361 TAGCTGAGTATGGGGCAAGCACTATAGTCCCGGGCTACTGGAGCTGGCC 418
 Db 361 TAGCTGAGTATGGGGCACTATAGTCCCGGGCTACTANGGAAGCTAGGGC 418

ALIGNMENTS

for SEQ ID NO:1360

RESULT 1
ABL65990
ID ABL65990 standard; DNA; 436 BP.
XX
AC ABL65990;
XX
DT 15-MAY-2002 (first entry)
XX
DE Lung cancer related gene sequence SEQ ID NO:4327.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW gene; ds; cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
XX
OS Homo sapiens.
XX
PN WO200194629-A2.
XX
PD 13-DEC-2001.
XX
PR 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233133P.
PR 20-SEP-2000; 2000US-23361P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 22-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-23409P.
PR 22-SEP-2000; 2000US-234567P.

A8L65490 for SEQ ID N 0 1306

PR 25-SEP-2000; 2000US-234923P. Db 1 TTATTTTTTTTTGAGGGTAGACGCCAGCTCATTTTATATAATTATAGAAA 60

PR 25-SEP-2000; 2000US-235077P. QY 61 ATACAGGCATTTAAATGAAACGTAGAAGATGTCACAGGAATAACAAT 120

PR 25-SEP-2000; 2000US-235082P. Db 61 ATACAGGCATTTAAATGAAACGTAGAAGATGTCACAGGAATAACAAT 120

PR 26-SEP-2000; 2000US-235637P. QY 121 ATATCACAAATAAAAGTACCCAGTAACAGTTACTAACAGAACCCAGCACC 180

PR 27-SEP-2000; 2000US-235711P. Db 121 ATATCACAAATAAAAGTACCCAGTAACAGTTACTAACAGAACCCAGCACC 180

PR 27-SEP-2000; 2000US-235840P. QY 181 ATCTGGACTTTTGCTAAGTCAGTCAGAGCAGCACTACGAGGAGATGTC 240

PR 28-SEP-2000; 2000US-236032P. Db 181 ATCTGGACTTTTGCTAAGTCAGTCAGAGCAGCACTACGAGGAGATGTC 240

PR 28-SEP-2000; 2000US-236033P. QY 241 CTGCTTTGGAGAGCAGTGGTCTGCAGTGGTTAAACCACTCCCTTCTCG 300

PR 28-SEP-2000; 2000US-236108P. Db 301 AACAGTTAGTCCGTCAGAGAAGACATTGACATCGGTGGCTTACATTC 360

PR 29-SEP-2000; 2000US-236894P. QY 361 CACCATTTAACGGAGACTGGCAACACTGTATGAGAGGAGACCGCTCAGCCAG 420

PR 02-OCT-2000; 2000US-237172P. Db 361 CACCATTTAACGGAGACTGGCAACACTGTATGAGAGGAGACCGCTCAGCCAG 420

PR 02-OCT-2000; 2000US-237173P. QY 421 GCGGGAGTCACTG 436

PR 02-OCT-2000; 2000US-237298P. Db 421 GCGGGAGTCACTG 436

PR 02-OCT-2000; 2000US-237299P. QY 301 AACAGTTAGTCCGTCAGAGAAGACATTGACATCGGTGGCTTACATTC 360

PR 02-OCT-2000; 2000US-237316P. Db 301 AACAGTTAGTCCGTCAGAGAAGACATTGACATCGGTGGCTTACATTC 360

PR 03-OCT-2000; 2000US-237455P. QY 361 CACCATTTAACGGAGACTGGCAACACTGTATGAGAGGAGACCGCTCAGCCAG 420

PR 03-OCT-2000; 2000US-237588P. Db 361 CACCATTTAACGGAGACTGGCAACACTGTATGAGAGGAGACCGCTCAGCCAG 420

PR 03-OCT-2000; 2000US-237604P. QY 421 GCGGGAGTCACTG 436

PR 03-OCT-2000; 2000US-237608P. Db 421 GCGGGAGTCACTG 436

PR 01-NOV-2000; 2000US-244867P. QY 301 AACAGTTAGTCCGTCAGAGAAGACATTGACATCGGTGGCTTACATTC 360

PR 01-NOV-2000; 2000US-245084P. Db 361 CACCATTTAACGGAGACTGGCAACACTGTATGAGAGGAGACCGCTCAGCCAG 420

PA (AVAL-) AVALON PHARM. QY 421 GCGGGAGTCACTG 436

XX YY
PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;

PI Soppel DR, Weaver Z;
XX DR WPI: 2002-188264/24.

PR Screening for anti-neoplastic agent involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, and determining a change in expression of a gene of a signature gene set -

PS Claim 1; SEQ ID N 327; 44pp; English.

XX

The present invention describes a method (M1) for screening for an anti-neoplastic agent. The method involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, determining a change in expression of at least one gene (I) of a signature gene set, where (I) comprises a sequence (S) selected from 8447 sequences (given in ABL16164 to ABL70110), or is at least 95% identical to (S), where a change in expression is indicative of anti-neoplastic activity. (I) has cytostatic activity and can be used in gene therapy. M1 can be used for screening an anti-neoplastic agent, and can be used for producing a product which is the data collected with respect to the anti-neoplastic agent as a result of M1, and the data is sufficient to convey the chemical structure and/or properties of the agent. M1 can be used in the treatment of cancer such as colon, breast, stomach, lung, thyroid, oesophageal, ovarian, kidney, prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer, infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilm's tumour.

XX Sequence 436 BP; 143 A; 88 C; 90 G; 115 T; 0 other;

Query Match 100.0%; Score 436; DB 24; Length 436;

Best Local Similarity 100.0%; Pred. No. 2. 2e-88; Matches 436; Conservative 0; Mismatches 0; Index 0; Gaps 0;

Tue May 27 08:34:31 2003

us-09-954-

f- S7Q 1D ~0:1300

RESULT 1
AA410986
LOCUS AA410986 436 bp mRNA linear EST 18-MAY-1997
DEFINITION similar to TR:G642072 G642072 FIBRILLIN-1 ; mRNA sequence.
ACCESSION AA410986
VERSION AA410986.1 GI:2070092
KEYWORDS EST,
SOURCE human.
ORGANISM Homo sapiens

REFERENCE Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo;
AUTHORS 1 (bases 1 to 436)
Hillier,L., Allén,M., Bowles,L., Dubuque,T., Geisel,G., Jost,S.,
Kubala,T., Lacy,M., Le,N., Lennon,G., Marra,M., Martin,J., Moore,B.,
, Schellenberg,K., Steptoe,M., Tan,F., Theising,B., White,Y., Wylie,
, T., Waterston,R. and Wilson,R.

TITLE WasU-Merck EST Project 1997
JOURNAL Unpublished (1997)
COMMENT Contact: Wilson RK

Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu

This clone is available royalty-free through LILN; contact the
IMAGE Consortium (infoimage.lnl.gov) for further information.
Possible reversed clone: similarity on wrong strand
Seq primer: -41ml3 fwd. ET from Amersham

BASE COUNT 143 a 88 c 90 g 115 t

ORIGIN

Query Match 100 %; Score 436; DB 9; Length 436;

Best Local Similarity 100 %; Pred. No. 1.le-65; Mismatches 436; Conservative 0; Indels 0; Gaps 0;

QY	1	TTTTTTTTTTTTTGAGGGTAGAGCAGCATATTATTAATTTTATAGAA	60
Db	1	TTTTTTTTTTTTTTTGAGGGTAGAGCAGCATATTATTAATTTTATAGAA	60
QY	61	ATACAGGCATTTAACATGGAACATGTAGAAGATGTACAGGATACAAAT	120
Db	61	ATACAGGCATTTAACATGGAACATGTAGAAGATGTACAGGATACAAAT	120
QY	121	ATATCACAAATAAAAGTACCCAAAGTACACAGTTACACAGGATACCC	180
Db	121	ATATCACAAATAAAAGTACCCAAAGTACACAGGATACACAGGATACCC	180
QY	181	ATGTTGACTCTCTTGATAGTCAGATGCCAGGAGCTACCGGAGGAGATGTC	240
Db	181	ATGTTGACTCTCTTGATAGTCAGATGCCAGGAGCTACCGGAGGAGATGTC	240
QY	241	CGCTTTGGAGGAGCCAGATGTCAGTGTCAAGCTAACCCACTCCCTCTTCTCG	300
Db	241	CGCTTTGGAGGAGCCAGATGTCAGTGTCAAGCTAACCCACTCCCTCTTCTCG	300
QY	301	AACAGTATGTCGCCAGAGAACATGTACATCGGGTGGCTTACACATTTC	360
Db	301	AACAGTATGTCGCCAGAGAACATGTACATCGGGTGGCTTACACATTTC	360
QY	361	CACCATTTAACAGGGAGACTGCAACACGCTGATGACAGGAGACCCGTCAGCCAG	420
Db	361	CACCATTTAACAGGGAGACTGCAACACGCTGATGACAGGAGACCCGTCAGCCAG	420
QY	421	GCGGCACTCACTG	436
Db	421	GCGGCACTCACTG	436

ALIGNMENTS

for SETA 1b nu: 1346

RESULT 1
AA62085
LOCUS AA620885
DEFINITION af9906.s1 Soares-testis_NHT Homo sapiens cDNA clone IMAGE:1055578
3', mRNA sequence.
ACCESSION AA620885
VERSION AA620885.1 GI:2524824
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 383)
AUTHORS Hillier,L., Allen,M., Bowles,L., Duboque,T., Geisel,G., Jost,S.,
Kriman,D., Kucaba,T., Lacy,M., Le,N., Lennon,G., Marra,M., Martin,
,J., Moore,B., Schellenberg,K., Steptoe,M., Tan,F., Theising,B.,
White,Y., Wyllie,T., Waterston,R. and Wilson,R.
TITLE WashU-NCI human EST Project
JOURNAL Unpublished (1997)
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@wuston.wustl.edu
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (infoimage.llnl.gov) for further information.
'Insert Length: 1052 Std Error: 0.00
Seq primer: -40ml3 fwd. ET from Amersham

- 954 -

True May 27 08:34:32 2003

RESULTS	DEFINITION	ACCSSION	VERSTION	KEYWORDS	SOURCE	ORGANISM	JOURNAL	COMMENT	FEATURES	SOURCE	BASE COUNT	DRIVEN														
AI368878	AI368878.1	AT368878.1	gW15A11.x1	MtRNA sequence	EST	Homo sapiens	Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;	Tumor gene index	Conjectet: Robert Krausberg, Ph.D.	Email:	157 a	68 C	46 g	142 t												
AI368878	AI368878.1	AT368878.1	gW15A11.x1	MtRNA sequence	EST	Homo sapiens	Eukaryota; Mollusca; Primates; Carcarhini; Hominidae; Homo.	Basereading length: 3608 Std Error: 0.00	DNA sequence analysis by: Greg Lennox, Ph.D.	Tissue Preparation: Life Technologies, Inc.	www-bio.ljll.jyu.ac.jp/bio/IMAGE/Image/	insert length: 3608 Std Error: 0.00	Seg primer: -400P from Gibson	clone length: 1151 IMAGE:1991132	/clone="IMAGE:1991132"	/db_xref="taxon:9606"	/organism="Homo sapiens"	/tissue-type="Poorly differentiated endometrial adenocarcinoma, 2 pooled tumors"	/label="host=DH10B"	Note_Organ: uterus, Vector: PCMV-SPORE, Site_1: SalI,	Site_2: NotI; Cloned undirectionally. Primer: Oligo dT.	Average insert size 1.45 kb. Life Technologies catalog #: 11541-018.	Best Locus Similarity 99.6%; Score 381.4; DB 9; Length 413;	Query Match 99.6%; Conservative 99.4%; Pred. No. 3, 3E-58;	Matches 382; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	5 TTAAACATAAAATTCTTAACTACGCAATGTTGCCTATA 60 5 TTAAACATAAAATTCTTAACTACGCAATGTTGCCTATA 64
AI368878	AI368878.1	AT368878.1	gW15A11.x1	MtRNA sequence	EST	Homo sapiens	Eukaryota; Primates; Carcarhini; Hominidae; Homo.	Basereading length: 3608 Std Error: 0.00	DNA sequence analysis by: Greg Lennox, Ph.D.	Tissue Preparation: Life Technologies, Inc.	www-bio.ljll.jyu.ac.jp/bio/IMAGE/Image/	insert length: 3608 Std Error: 0.00	Seg primer: -400P from Gibson	clone length: 1151 IMAGE:1991132	/clone="IMAGE:1991132"	/db_xref="taxon:9606"	/organism="Homo sapiens"	/tissue-type="Poorly differentiated endometrial adenocarcinoma, 2 pooled tumors"	/label="host=DH10B"	Note_Organ: uterus, Vector: PCMV-SPORE, Site_1: SalI,	Site_2: NotI; Cloned undirectionally. Primer: Oligo dT.	Average insert size 1.45 kb. Life Technologies catalog #: 11541-018.	Best Locus Similarity 99.6%; Score 381.4; DB 9; Length 413;	Query Match 99.6%; Conservative 99.4%; Pred. No. 3, 3E-58;	Matches 382; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	5 TTAAACATAAAATTCTTAACTACGCAATGTTGCCTATA 60 5 TTAAACATAAAATTCTTAACTACGCAATGTTGCCTATA 64

¹ Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S; PI Soppet DR, Weaver Z; XX WDR - 2000 1995

ID ABL62811 standard; DNA; 383 BP.
XX
AC ABL62811;

(first entry)

Breast cancer related gene sequence SEQ ID NO:1148.

Human; cancer; colon; brea-

cytostatic; gene therapy; pa-

PN	W0200194629-A2.
XX	
PD	13-DEC-2001.
XX	
PF	30-MAY-2001; 2001MO-US10838
XX	
PR	05-JUN-2000; 2000US-209473P
PR	05-JUN-2000; 2000US-209531P
PR	18-SEP-2000; 2000IS-23131P
PR	18-SEP-2000; 2000IS-233617P
PR	20-SEP-2000; 2000IS-234009P
PR	20-SEP-2000; 2000IS-234340P
PR	20-SEP-2000; 2000IS-234502P
PR	22-SEP-2000; 2000IS-234509P
PR	22-SEP-2000; 2000IS-234567P

June May 6, 1939: 31

us-09-954-45

	matches	conservative	missed	indels	gaps
OY	383;	383;	5.8e-66;	0;	0;

PR	25-SEP-2000;	2000US-234923P
PR	25-SEP-2000;	2000US-234924P
PR	25-SEP-2000;	2000US-234924P
PR	25-SEP-2000;	2000US-235082P
PR	25-SEP-2000;	2000US-235134P
PR	25-SEP-2000;	2000US-235280P
PR	26-SEP-2000;	2000US-235280P
PR	26-SEP-2000;	2000US-235638P
PR	27-SEP-2000;	2000US-235711P
PR	27-SEP-2000;	2000US-235711P
PR	27-SEP-2000;	2000US-235840P
PR	27-SEP-2000;	2000US-235863P
PR	28-SEP-2000;	2000US-236032P
PR	28-SEP-2000;	2000US-236032P
PR	28-SEP-2000;	2000US-236033P
PR	28-SEP-2000;	2000US-236034P
PR	28-SEP-2000;	2000US-236109P
PR	29-SEP-2000;	2000US-236111P
PR	29-SEP-2000;	2000US-236842P
PR	02-OCT-2000;	2000US-236891P
PR	02-OCT-2000;	2000US-237112P
PR	02-OCT-2000;	2000US-237173P
PR	02-OCT-2000;	2000US-237279P
PR	02-OCT-2000;	2000US-237299P
PR	02-OCT-2000;	2000US-237299P
PR	03-OCT-2000;	2000US-237311P
PR	03-OCT-2000;	2000US-237422P
PR	03-OCT-2000;	2000US-237422P
PR	03-OCT-2000;	2000US-237609P
PR	03-OCT-2000;	2000US-237609P
PR	03-OCT-2000;	2000US-237609P
PR	01-NOV-2000;	2000US-244867P
PR	01-NOV-2000;	2000US-245084P

Tue May 27 08:34:34 2003

us-09-954

RESULT 1 NS2026 Locus 5070 ID: M483
 LOCUS N52026 Definition Soares_multiple_sclerosis_2NbHMSP Homo sapiens cDNA
 DEFINITION Y208e07.s1 Soares_multiple_sclerosis_2NbHMSP Homo sapiens cDNA
 ACCESSION N52026
 VERSION N52026.1 GI:1193192
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 486)
 AUTHORS Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M., Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marras,M., Parsons,J., Rikfin,L., Rohlfing,T., Soares,M., Tan,F., Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and Wilson,R.
 TITLE The WashU-Merck EST Project
 JOURNAL Unpublished (1995)
 COMMENT Contact: Wilson RK
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: est@watson.wustl.edu
 This clone is available royalty-free through LInL ; contact the IMAGE Consortium (info@image.lnl.gov) for further information.
 Seq primer: m13 -40 forward
 High quality sequence stop: 194.

BASE COUNT 157 a 85 c 94 g 147 t 3 others
 ORIGIN G. Becker (NIH/NIDR). " kindly provided by Dr. Kevin

FEATURES source
 Location/Qualifiers
 /organism="Homo sapiens"
 /db_xref="GDB:3900966"
 /clone_line="Soares_multiple_sclerosis_2NbHMSP"
 /sex="male"
 /tissue_type="multiple sclerosis lesions"
 /dev_stage="Age 46"
 /lab_host="DH10B (ampicillin resistant)"
 /note="Vector: PT773 (Pharmacia) With a modified polylinker V-type; Phagemid; Site_1: Not I; Site_2: Eco RI
 primer 5' TGTTCACACTGAGTGGGGCCATTTTTTTTTTTTTTTTTTT
 double-stranded cDNA was size selected, ligated to Eco RI
 adaptors (Pharmacia), digested with Not I and cloned into
 the Not I and Eco RI sites of a modified PT773 vector
 (Pharmacia). Library went through one round of
 normalization to a Cot = 5. Library constructed by Bent
 Soares and M. Patina Bonaldo. RNA from 4 multiple sclerosis
 lesions from one patient was kindly provided by Dr. Kevin
 G. Becker (NIH/NIDR). "
 Best Local Similarity 99.4%; Score 483; DB 14; Length 486;
 Matches 486; Conservative 0; Mismatches 0; Gaps 0;
 Query 1 ACCCTGAGATAGATGATTATAGCAGAGGAACTATTTACAA 60
 Db 1 ACCCTGAGATAGATGATTATAGCAGAGGAACTATTTACAA 60
 Query 61 ATGGAATTTTTCACACAACTGCTGAACTGAAATTTAGGATATAAT 120
 Db 61 ATGGAATTTTTCACACAACTGCTGAACTGAAATTTAGGATATAAT 120
 Query 121 TCTCATACCACTAGTAGTGCCTACAGCAAAGTGCTGTGTGTAGTGAGATGC 180
 Db 121 TCTCATACCACTAGTAGTGCCTACAGCAAAGTGCTGTGTGTAGTGAGATGC 180
 Query 181 CTGCCACTCGGACTTAACCTGTTCTATCTGTTCTACAGTGTAAACATGGTA 240
 Db 181 CTGCCACTCGGACTTAACCTGTTCTACAGTGTAAACATGGTA 240
 Query 241 TATCCACAGAATAGCACTACATCTACATATCTCTGCTAGAGGCATTAGCAGAGCA 300
 Db 241 TATCCACAGAATAGCACTACATCTACATATCTCTGCTAGAGGCATTAGCAGAGCA 300
 Query 301 CASTATANGCCATAAACACTGGTTATGGATTTCCTATTCCTACAGTGGGTTA 360
 Db 301 CASTATANGCCATAAACACTGGTTATGGATTTCCTATTCCTACAGTGGGTTA 360
 Query 361 CTAATTATCCACCAAGTATCNGACTTAAAGCCATCTCAATGGTAGGCTGCTGA 420
 Db 361 CTAATTATCCACCAAGTATCNGACTTAAAGCCATCTCAATGGTAGGCTGCTGA 420
 Query 421 AGTGGACCGGTANGCAGCCATAAGANGGAAAAGTGACATTGGGTTCCCGACT 480
 Db 421 AGTGGACCGGTANGCAGCCATAAGANGGAAAAGTGACATTGGGTTCCCGACT 480
 Query 481 TCAGTG 486
 Db 481 TCAGTG 486

ALIGNMENTS

For SETQ 1D No: 1483

RESULT 1
ABL6617³
ID ABL66173 standard; DNA; 486 BP.
XX
AC ABL66173;
XX
XX
DT 15-MAY-2002 (first entry)
XX
DE Lung cancer related gene sequence SEQ ID NO:4510.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds;
XX
OS Homo sapiens.
XX
PN WC200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-231133P.
PR 18-SEP-2000; 2000US-231617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.

PR 25-SEP-2000; 2000US-234923P. Db 1 ACCCTGAGATAGAATAGATTATAGCAGAGGAAATCAGGAACATATTTACAA 60
 PR 25-SEP-2000; 2000US-234924P. Qy 61 ATGGAAATTTCACAAACAGCTGAAAGGAAATTCTTGGGATGAAAT 120
 PR 25-SEP-2000; 2000US-235077P. Db 61 ATGGAATTTTCCAAACAGCTGAAAGGAAATTCTTGGGATGAAAT 120
 PR 25-SEP-2000; 2000US-235134P. Qy 121 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 120
 PR 26-SEP-2000; 2000US-235082P. Db 121 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 120
 PR 26-SEP-2000; 2000US-235638P. Qy 180 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 180
 PR 27-SEP-2000; 2000US-235711P. Db 121 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 180
 PR 27-SEP-2000; 2000US-235720P. Qy 181 CTGCCACTCGGAGTAACCTGGTTCTATACTGTCAGCTAAATCATGTTA 240
 PR 27-SEP-2000; 2000US-235863P. Db 181 CTGCCACTCGGAGTAACCTGGTTCTATACTGTCAGCTAAATCATGTTA 240
 PR 28-SEP-2000; 2000US-236032P. Db 240
 PR 28-SEP-2000; 2000US-236033P. Db 240
 PR 28-SEP-2000; 2000US-236034P. Db 240
 PR 28-SEP-2000; 2000US-236109P. Db 240
 PR 28-SEP-2000; 2000US-236111P. Db 240
 PR 29-SEP-2000; 2000US-236812P. Db 300
 PR 02-OCT-2000; 2000US-237172P. Db 360
 PR 02-OCT-2000; 2000US-237173P. Db 360
 PR 02-OCT-2000; 2000US-237278P. Db 360
 PR 02-OCT-2000; 2000US-237294P. Db 360
 PR 02-OCT-2000; 2000US-237295P. Db 360
 PR 02-OCT-2000; 2000US-237316P. Db 360
 PR 03-OCT-2000; 2000US-237425P. Db 360
 PR 03-OCT-2000; 2000US-237598P. Db 360
 PR 03-OCT-2000; 2000US-237604P. Db 360
 PR 03-OCT-2000; 2000US-237606P. Db 360
 PR 01-NOV-2000; 2000US-244857P. Db 420
 PR 01-NOV-2000; 2000US-245084P. Db 420
 PR (AVAL-) AVALON PHAR[†] Db 420
 XX PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S; Db 420
 PI Soppet DR, Weaver Z; DR WPI: 2002-188264/24. Db 420
 XX PT Screening for anti-neoplastic agent involves exposing cells to a Db 420
 PT chemical agent to be tested for anti-neoplastic activity, and determining a change in expression of a gene of a signature gene set. Db 420
 PS Claim 1; SEQ ID 4510; 44pp; English. Db 420
 XX The present invention describes a method (M1) for screening for an anti-neoplastic agent. The method involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, determining a change in expression of at least one gene (I) of a signature gene set, where (I) comprises a sequence (S) selected from 8447 sequences (given in AB161664 to AB170110), or is at least 95% identical to (S), where a change in expression is indicative of anti-neoplastic activity. (I) has cytostatic activity and can be used in gene therapy. M1 can be used for screening an anti-neoplastic agent, and can be used for producing a product which is the data collected with respect to the anti-neoplastic agent as a result of M1, and the data is sufficient to convey the chemical structure and/or properties of the agent. M1 can be used in the treatment of cancer such as, colon, breast, stomach, lung, thyroid, oesophageal, ovarian, kidney, prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell cancer, infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilms' tumour. Db 420
 SO Sequence 486 BP; 157 A; 85 C; 94 G; 147 T; 3 other; Db 420
 Query Match 99.4%; Score 483; DB 24; Length 486;
 Best Local Similarity 100.0%; Pred. No. 7.6e-124; Mismatches 0; Indels 0; Gaps 0;
 Matches 486; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 ACCCGAGAGAGAGATGATTAGCAAGGATACGAGAACATATAATTCTACAA 60
 ||||||| 61 ATGGAAATTTCACAAACAGCTGAAAGGAAATTCTTGGGATGAAAT 120
 ||||||| 121 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 120
 ||||||| 180 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 180
 ||||||| 181 CTGCCACTCGGAGTAACCTGGTTCTATACTGTCAGCTAAATCATGTTA 240
 ||||||| 181 CTGCCACTCGGAGTAACCTGGTTCTATACTGTCAGCTAAATCATGTTA 240
 ||||||| 240 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 240
 ||||||| 241 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 240
 ||||||| 300 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 300
 ||||||| 360 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 360
 ||||||| 360 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 360
 ||||||| 360 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 360
 ||||||| 420 TCTCATACCACTAGGTATGCCAACAGCTGAAAGGAAATTCTTGGGATGAAAT 420
 ||||||| 420 AGTGACCGGTANGAGCTTAAGANGAAAGTAGCATTTGGGTTCCCGACTT 480
 ||||||| 421 AGTGACCGGTANGAGCTTAAGANGAAAGTAGCATTTGGGTTCCCGACTT 480
 ||||||| 480 AGTGACCGGTANGAGCTTAAGANGAAAGTAGCATTTGGGTTCCCGACTT 480
 ||||||| 481 TCAGTG 486
 ||||||| 481 TCAGTG 486

ALIGNMENTS

for SEQ ID NO: 1579

RESULT 1
H98215 383 bp mRNA linear EST 12-DEC-1995
LOCUS H98215 YY09402.s1 Soares melanocyte 2NBHM Homo sapiens cDNA clone
DEFINITION YY09402.s1 Soares melanocyte 2NBHM Homo sapiens cDNA clone
IMAGE:261194 3', mRNA sequence.
ACCESSION H98215
VERSION H98215.1 GI:1119100
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 383)
AUTHORS Hillier,L., Clark,N., Dubroque,T., Elliston,K., Hawkins,M., Holman
,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M., Parsons,J.,
Riffkin,L., Rohlfing,T., Soares,M., Tan,F., Trevaskis,E., Waterston
,R., Williamson,A., Woldmann,P. and Wilson,R.
TITLE The WashU-Merck EST Project
JOURNAL Unpublished (1995)
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@wustl.edu
High quality sequence stops: 109
Source: IMAGE Consortium, LBL
This clone is available royalty-free through LBL ; contact the
IMAGE consortium (info@image.lbl.gov) for further information.

FEATURES	TITLE	National Institutes of Health, Mammalian Gene Collection (MGC)
FEATURES	JOURNAL	Unpublished (1999)
FEATURES	COMMENT	Contact: Robert Strausberg, Ph.D. Email: csgaps-l@mail.nih.gov
Source		
1. .383		
/organism="Homo sapiens"		
/db_xref="GB:387083"		
/clone="IMAGE:261194"		
/clone_libraries=melanocyte 2nbhm		
/sex="Male"		
/tissue_type="melanocyte"		
/lab_host=DH10B (ampicillin resistant)"		
/note="Vector: pT73D (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dt) primer [5', double-stranded cDNA was size selected, ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pT73 vector (Pharmacia). Library constructed by Bento Soares and M.Fatima Bonaldo. RNA from normal foreskin melanocytes (PMV374) was kindly provided by Dr. Anthony P. Albino."		
BASE COUNT		
139 a 65 c 80 g 96 t		
ORIGIN		
Query Match		
Best Local Similarity 99.2%; Score 380; DB 14;		
Matches 383; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Db		
1 CACAGGAACTTTCATGGAGAATAAGCCCTGTTGCTAACGTG 60		
2 CACAGGAACTTTCATGGAGAATAAGCCCTGTTGCTAACGTG 60		
Oy		
1 61 CAACTACAGATAATTGTAAGAAAGAGGGAACGGGAAGGGAAGAACCTTT 120		
2 61 CAACATACAGATAATTGTAAGAAAGAGGGAACGGGAAGGGAACACCTTT 120		
Qy		
1 121 GAGGCCAAAGTGNCACAAAAATGCTAAAGATTCTCAGCAGANGCATTTT 180		
2 121 GAGGCCAAAGTGNCACAAAAATGCTAAAGATTCTCAGCAGANGCATTTT 180		
Db		
1 181 GCAATACATGCAAACAGGGAGCTGTTAGAGATCCCTATAATACAGA 240		
2 181 GCAATACATGCAAACAGGGAGCTGTTAGAGATCCCTATAATACAGA 240		
Oy		
1 241 AAAGACACTCCAAAGCATCTCTGTGACTCGAGCACAGAGAAAGAACTAATAG 300		
2 241 AAAGACACTCCAAAGCATCTCTGTGACTCGAGCACAGAGAAAGAACTAATAG 300		
Qy		
1 301 CCTTTGGATTCAAGATAATTGTCAGTACATTTTACAGTCCTAA 360		
2 301 CCTTTGGATTCAAGATAATTGTCAGTACATTTTACAGTCCTAA 360		
Oy		
1 361 GGGGAAATAACTGACATAATTT 383		
2 361 GGGGAAATAACTGACATAATTT 383		
Db		
1 361 GGGGAAATAACTGACATAATTT 383		
RESULT		
2 B820748/c		
LOCUS B1820748		
DEFINITION 60304344FL NIH_MGC_115 Homo sapiens mRNA linear EST 04-OCT-2001		
ACCESSION B1820748		
VERSION B1820748.1		
KEYWORDS EST.		
SOURCE human.		
ORGANISM Homo sapiens		
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
REFERENCE 1 (bases 1 to 463)		
AUTHORS NIH-MGC http://mgc.ncbi.nlm.nih.gov/		
RESULT		
3 B1715330		
LOCUS B1715330		
DEFINITION ic3fl12.1 Homo sapiens mRNA 5' linear EST 19-SEP-2001		
ACCESSION B1715330		
VERSION B1715336.1		
KEYWORDS EST.		

f Seq ID no: 1549

Tue May 27 08:34:34 2003

us-09-954-

CC is the data collected with respect to the anti-neoplastic agent as a result of M₁, and the data is sufficient to convey the chemical structure and/or properties of the agent. M₁ can be used in the treatment of cancer such as colon, breast, stomach, lung, thyroid, oesophageal, ovarian, kidney, prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell cancer, infiltrating lobular carcinoma, papillary carcinoma, squamous cell carcinoma, neuroendocrine carcinoma, and Wilms tumour.

SQ Sequence 383 BP; 139 A; 65 C; 80 G; 96 T; 3 other;

Query Match 99.2%; Score 380; DB 24; Length 383;
Best Local Similarity 100.0%; Pred. No. 1.8e-100;
Matches 383; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CACAGGACAACTCCTTATGTACATUGGAGATAACCCCTGTGCTGGTCACGGTG	60
Db	1	CACAGGACACATTCTTATGTACATUGGAGATAACCCCTGTGCTGGTCACGGTG	60
QY	61	CAACATACAGAATTTGATTAAGAAAGAGGAAACGGGAAGGGANGGAACCTTT	120
Db	61	CAACATACAGAATTTGATTAAGAAAGAGGAAACGGGAAGGGANGGAACCTTT	120
QY	121	GAGTCACAAGTGTGNCACAAAATGTTAAAGATTTCCMCACCGAAGANGGATT	120
Db	121	GAGTCACAAGTGTGNCACAAAATGTTAAAGATTTCCMCACCGAAGANGGATT	120
QY	181	GCAATACCATGCAAACAGGCAGCTGGTGCCATTAGAGAAATCCCATAATACGA	240
Db	181	GCAATACCATGCAAACAGGCAGCTGGTGCCATTAGAGAAATCCCATAATACGA	240
QY	241	AAAGACTCTCAGGATTCCTGTAGTTGACTCAGAGCAGAAAGAAACTTAAATG	300
Db	241	AAAGACTCTCAGGATTCCTGTAGTTGACTCAGAGCAGAAAGAAACTTAAATG	300
QY	301	CCTTGATTCAGATATTGSCACTCTGTGATTCATTTTACGTCATTAATG	300
Db	301	CCTTGATTCAGATATTGSCACTCTGTGATTCATTTTACGTCATTAATG	360
QY	361	GGGGATAACTGACATAATT	383
Db	361	GGGGATAACTGACATAATT	383

for SEQ ID NO: 1549

RESULT 1

ABL62348

ID

ABL62348 standard; DNA; 383 BP.

XX

AC

ABL62348;

XX

DT

15-MAY-2002 (first entry)

XX

DE

Colon adenocarcinoma related gene sequence SEQ ID NO:685.

XX

KW

Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;

KW

stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;

KW

cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;

KW

gene; ds.

XX

OS

Homo sapiens.

XX

PN

WO200194629-A2.

XX

PD

13-DEC-2001.

XX

PP

30-MAY-2001; 2001WO-US10838.

XX

PR

05-JUN-2000; 2000US-203473P.

PR

05-JUN-2000; 2000US-209531P.

PR

18-SEP-2000; 2000US-233133P.

PR

18-SEP-2000; 2000US-233617P.

PR

20-SEP-2000; 2000US-234009P.

PR

20-SEP-2000; 2000US-234034P.

PR

20-SEP-2000; 2000US-234052P.

PR

22-SEP-2000; 2000US-234569P.

PR

22-SEP-2000; 2000US-234567P.

PR 25-SEP-2000; 2000US-234923P.
 PR 25-SEP-2000; 2000US-234924P.
 PR 25-SEP-2000; 2000US-235077P.
 PR 25-SEP-2000; 2000US-235082P.
 PR 25-SEP-2000; 2000US-235134P.
 PR 26-SEP-2000; 2000US-235637P.
 PR 27-SEP-2000; 2000US-235711P.
 PR 27-SEP-2000; 2000US-235720P.
 PR 27-SEP-2000; 2000US-235840P.
 PR 27-SEP-2000; 2000US-235863P.
 PR 28-SEP-2000; 2000US-236028P.
 PR 28-SEP-2000; 2000US-236032P.
 PR 28-SEP-2000; 2000US-236033P.
 PR 28-SEP-2000; 2000US-236034P.
 PR 28-SEP-2000; 2000US-236109P.
 PR 28-SEP-2000; 2000US-236111P.
 PR 29-SEP-2000; 2000US-236842P.
 PR 02-OCT-2000; 2000US-237172P.
 PR 02-OCT-2000; 2000US-237173P.
 PR 02-OCT-2000; 2000US-237278P.
 PR 02-OCT-2000; 2000US-237294P.
 PR 02-OCT-2000; 2000US-237316P.
 PR 03-OCT-2000; 2000US-237425P.
 PR 03-OCT-2000; 2000US-237598P.
 PR 03-OCT-2000; 2000US-237600P.
 PR 01-NOV-2000; 2000US-244867P.
 PR 01-NOV-2000; 2000US-245084P.
 PA (AVAL-) AVALON PHARM.
 PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
 PI Soppet DR, Weaver Z;
 XX DR WPI; 2002-188264/24.

PT Screening for anti-neoplastic agent involves exposing cells to a
 PT chemical agent to be tested for anti-neoplastic activity, and
 determining a change in expression of a gene of a signature gene set
 PS Claim 1; SEQ ID 685; 44PP; English.

XX
 CC The present invention describes a method (M1) for screening for an
 CC anti-neoplastic agent. The method involves exposing cells to a chemical
 CC agent to be tested for anti-neoplastic activity, determining a change in
 expression of at least one gene (1) of a signature gene set, where (1)
 CC comprises a sequence (S) selected from 8447 sequences (given in AB16164
 CC to AB170110), or is at least 95% identical to (S), where a change in
 expression is indicative of anti-neoplastic activity. (1) has cytostatic
 CC activity and can be used in gene therapy. M1 can be used for screening
 CC an anti-neoplastic agent, and can be used for producing a product which
 CC is the data collected with respect to the anti-neoplastic agent as a
 CC result of M1, and the data is sufficient to convey the chemical
 CC structure and/or properties of the agent. M1 can be used in the
 CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
 CC oesophageal, ovarian, prostate or pancreatic cancer, adenocarcinoma,
 CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
 CC carcinoma, papillary carcinoma and Wilms' tumour.
 XX Sequence 383 BP; 139 A; 65 C; 80 G; 96 T; 3 other;

Query Match 99.2%; Score 380; DB 24; Length 383;
 Best Local Similarity 100.0%; Pred. No. 1.8e-100;
 Matches 383; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CACAGGAACTATCTTTATTGTGAGAAATAGCCTCGTGTGCTCAAGGTG 60
 PR 26-SEP-2000; 2000US-235637P.
 PR 26-SEP-2000; 2000US-235638P.
 PR 27-SEP-2000; 2000US-235711P.
 PR 27-SEP-2000; 2000US-235720P.
 PR 27-SEP-2000; 2000US-235840P.
 PR 27-SEP-2000; 2000US-236028P.
 PR 28-SEP-2000; 2000US-236032P.
 PR 28-SEP-2000; 2000US-236033P.
 PR 28-SEP-2000; 2000US-236034P.
 PR 28-SEP-2000; 2000US-236109P.
 PR 28-SEP-2000; 2000US-236111P.
 PR 29-SEP-2000; 2000US-236842P.
 PR 02-OCT-2000; 2000US-237172P.
 PR 02-OCT-2000; 2000US-237173P.
 PR 02-OCT-2000; 2000US-237278P.
 PR 02-OCT-2000; 2000US-237294P.
 PR 02-OCT-2000; 2000US-237316P.
 PR 03-OCT-2000; 2000US-237425P.
 PR 03-OCT-2000; 2000US-237598P.
 PR 03-OCT-2000; 2000US-237600P.
 PR 01-NOV-2000; 2000US-244867P.
 PR 01-NOV-2000; 2000US-245084P.

RESULT 2
 AB165156
 ID ABL65156 standard; DNA; 383 BP.
 XX
 AC ABL65156;
 XX
 DT 15-MAY-2002 (first entry)
 XX DE Lung cancer related gene sequence SEQ ID NO:3493.
 XX Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
 KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
 KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
 KW gene; ds;
 XX OS Homo sapiens.
 XX PN WO20014629-A2.
 XX PD 13-DEC-2001.
 XX
 PF 30-MAY-2001; 2001WO-US10838.
 PR 05-JUN-2000; 2000US-09473P.
 PR 05-JUN-2000; 2000US-209531P.
 PR 18-SEP-2000; 2000US-233133P.
 PR 18-SEP-2000; 2000US-233617P.
 PR 20-SEP-2000; 2000US-234009P.
 PR 20-SEP-2000; 2000US-234034P.
 PR 22-SEP-2000; 2000US-234052P.
 PR 22-SEP-2000; 2000US-234505P.
 PR 22-SEP-2000; 2000US-234567P.
 PR 25-SEP-2000; 2000US-234923P.
 PR 25-SEP-2000; 2000US-234944P.
 PR 25-SEP-2000; 2000US-235082P.
 PR 25-SEP-2000; 2000US-235144P.
 PR 25-SEP-2000; 2000US-235200P.
 PR 26-SEP-2000; 2000US-235637P.
 PR 26-SEP-2000; 2000US-235638P.
 PR 27-SEP-2000; 2000US-235711P.
 PR 27-SEP-2000; 2000US-235720P.
 PR 27-SEP-2000; 2000US-235840P.
 PR 28-SEP-2000; 2000US-236028P.
 PR 28-SEP-2000; 2000US-236032P.

Db 1 CACAGGAACTATCTTTATTGTGAGAAATAGCCTCGTGTGCTCAAGGTG 60
 QY 61 CACATACGAAATGGTAAAGAAGAGGAAACGGGAAGGAACCCCTT 120
 Db 61 CACATACGAAATGGTAAAGAAGAGGAAACGGGAAGGAAGGANGGAAACCTTT 120
 QY 121 GASSGCCAACAGTGNCACAAAATGTTAAGATTCCTCACGCAGANGGCATT 180
 Db 121 GAGGTCCAAGTGTGNCACAAATACTGGTAAAGATTCCTCACGCAGANGGCATT 180
 QY 181 GAAATACATGGAAACAGGCACTGTGCTTAGAGATCCOTATATACAGA 240
 Db 181 GCAAATACATGGAAACAGGCACTGTGCTTAGAGATCCOTATATACAGA 240
 QY 241 AAAGACACTCCAGCATCTCTACGGTGGACTCAGAGCACAGAGAAAGAACATAAT 300
 Db 241 AAAGACACTCCAGCATCTCTACGGTGGACTCAGAGCACAGAGAAAGAACATAAT 300
 QY 301 CCTTTGGATTGAGATTTGGCACTCTGTGATCATTTTACCTCCATAA 360
 Db 301 CCTTTGGATTGAGATTTGGCACTCTGTGATCATTTTACCTCCATAA 360
 QY 361 GGGGAATAACTGACATATAATT 383
 Db 361 GGGGAATAACTGACATATAATT 383

PR 28-SEP-2000; 20000US-236033P.
 PR 28-SEP-2000; 20000US-236014P.
 PR 28-SEP-2000; 20000US-236109P.
 PR 28-SEP-2000; 20000US-236111P.
 PR 29-SEP-2000; 20000US-236842P.
 PR 29-SEP-2000; 20000US-236891P.
 PR 02-OCT-2000; 20000US-237112P.
 PR 02-OCT-2000; 20000US-237113P.
 PR 02-OCT-2000; 20000US-237128P.
 PR 02-OCT-2000; 20000US-237294P.
 PR 02-OCT-2000; 20000US-237295P.
 PR 02-OCT-2000; 20000US-237316P.
 PR 03-OCT-2000; 20000US-237455P.
 PR 03-OCT-2000; 20000US-237598P.
 PR 03-OCT-2000; 20000US-237604P.
 PR 03-OCT-2000; 20000US-237605P.
 PR 03-OCT-2000; 20000US-237608P.
 PR 01-NOV-2000; 20000US-244867P.
 PR 01-NOV-2000; 20000US-245084P.
 PA (AVAL-) AVALON PHARM.
 PA XX
 PT Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
 PI Soppet DR, Weaver Z;
 XX DR WPI: 2002-188264/24.
 XX
 PT Screening for anti-neoplastic agent involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, and determining a change in expression of a gene of a signature gene set
 PS XX
 PT Claim 1; SEQ ID 3493; 44PP; English.
 XX
 CC The present invention describes a method (M1) for screening for an anti-neoplastic agent. The method involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, determining a change expression of at least one gene (1) of a signature gene set, where (1) comprises a sequence (S) selected from 847 sequences (given in ABL610 to ABL7011), or is at least 95% identical to (S), where a change in expression is indicative of anti-neoplastic activity. (1) has cyostatic activity and can be used in gene therapy. M1 can be used for screening an anti-neoplastic agent, and can be used for producing a product which is the data collected with respect to the anti-neoplastic agent as a result of M1, and the data is sufficient to convey the chemical structure and/or properties of the agent. M1 can be used in the treatment of cancer such as colon, breast, stomach, lung, thyroid, oesophageal, ovarian, kidney, prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer, infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilms' tumour.
 CC Sequence 383 BP; 139 A; 65 C; 80 G; 96 T; 3 other;
 CC SQ
 Query Match 99.2%; Score 380; DB 24; Length 383;
 Best Local Similarity 100.0%; Pred. No. 1 8e-100; Matches 383; Conservative 0; Mismatches 0; Indels 0; gaps 0
 Qy 1 CACAGGAACTATCTTGTATGGATCATGGAAATAGCCGCGTGCTGTTCAAGGT 60
 Db 1 CACAGGAACTATCTTGTATGGATCATGGAAATAGCCGCGTGCTGTTCAAGGT 60
 Qy 61 CAACATAGAAATGGATTAAGAAAGGGAGACGGGGAGGAACCTT 120
 Db 61 CAACATAGAAATGGATTAAGAAAGGGAGACGGGGAGGAACCTT 120
 Qy 121 GAGGTCACAAGTGTGCAACAAAAATGGTTAAAGATTCTCACCGCAGANGCATTTT 180
 Db 121 GAGGTCCAGTGTGCAACAAAATGGTAAGATTCTCACCGCAGANGCATT 180
 Qy 181 GCAATACTCATGCCAACAGGGAGCTGGTGCTTAGAGATCCCTATAACAGA 240
 Db 181 GCAATACTCATGCCAACAGGGAGCTGGTGCTTAGAGATCCCTATAACAGA 240

PR	03-OCT-2000;	2000US-237604P.	ABL66834
PR	03-OCT-2000;	2000US-237605P.	ID ABL66834 standard; DNA; 383 BP.
PR	03-OCT-2000;	2000US-237608P.	XX
PR	01-NOV-2000;	2000US-244867P.	AC ABL66834;
PR	01-NOV-2000;	2000US-245084P.	XX
PA	(AVAL-) AVALON PHARM.	DT 15 MAY-2002 (first entry)	XX
XX	Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;	DE Lung cancer related gene sequence SEQ ID NO:5171.	XX
PI	Soppet DR, Weaver Z;	KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid; stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous; cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma; gene; ds.	XX
PT		KW	XX
PT		OS Homo sapiens.	XX
PS		PN WO20019629-A2.	XX
XX		PD 13-DEC-2001.	XX
CC		PF 30-MAY-2001; 2001WO-US10838.	XX
CC		PR 05-JUN-2000; 2000US-209473P.	XX
CC		PR 05-JUN-2000; 2000US-209531P.	PR
CC		PR 18-SEP-2000; 2000US-23313P.	PR
CC		PR 18-SEP-2000; 2000US-233617P.	PR
CC		PR 20-SEP-2000; 2000US-234009P.	PR
CC		PR 20-SEP-2000; 2000US-234034P.	PR
CC		PR 20-SEP-2000; 2000US-234052P.	PR
CC		PR 22-SEP-2000; 2000US-234509P.	PR
CC		PR 22-SEP-2000; 2000US-234567P.	PR
CC		PR 25-SEP-2000; 2000US-234923P.	PR
CC		PR 25-SEP-2000; 2000US-234924P.	PR
CC		PR 25-SEP-2000; 2000US-235071P.	PR
CC		PR 25-SEP-2000; 2000US-235082P.	PR
CC		PR 25-SEP-2000; 2000US-235280P.	PR
CC		PR 25-SEP-2000; 2000US-235637P.	PR
CC		PR 26-SEP-2000; 2000US-235638P.	PR
CC		PR 27-SEP-2000; 2000US-235711P.	PR
CC		PR 27-SEP-2000; 2000US-235720P.	PR
CC		PR 27-SEP-2000; 2000US-235840P.	PR
CC		PR 27-SEP-2000; 2000US-235863P.	PR
Db	1 CACAGGACAACTTCTTTATGTCATGGAAATAGCCCTGTGCTGGTGAAGTGT 60	PR 28-SEP-2000; 2000US-236028P.	PR
Db	1 CACAGGACAACTTCTTTATGTCATGGAAATAGCCCTGTGCTGGTGAAGTGT 60	PR 28-SEP-2000; 2000US-236032P.	PR
Qy	61 CAACATACAGATAATGAAATAGAAAGGGAAAGGGAAAGGAAGGAAAGGAAAGG 120	PR 28-SEP-2000; 2000US-236033P.	PR
Qy	61 CAACATACAGATAATGAAATAGAAAGGGAAAGGGAAAGGGAAAGGGAAAGG 120	PR 28-SEP-2000; 2000US-236034P.	PR
Db	61 CAACATACAGATAATGAAATAGAAAGGGAAAGGGAAAGGGAAAGGGAAAGG 120	PR 28-SEP-2000; 2000US-236109P.	PR
Db	61 CAACATACAGATAATGAAATAGAAAGGGAAAGGGAAAGGGAAAGGGAAAGG 120	PR 28-SEP-2000; 2000US-236111P.	PR
Qy	121 GAGGTCAAAAGTTGNGAACAAAAAATGTAAGAGATTCTCACCAAGANGCATTT 180	PR 29-SEP-2000; 2000US-236842P.	PR
Qy	121 GAGGTCAAAAGTTGNGAACAAAAAATGTAAGAGATTCTCACCAAGANGCATTT 180	PR 02-OCT-2000; 2000US-237172P.	PR
Db	121 GAGGTCAAAAGTTGNGAACAAAAAATGTAAGAGATTCTCACCAAGANGCATTT 180	PR 02-OCT-2000; 2000US-237173P.	PR
Qy	181 GCAAATACCATGCAAAACAGCGCAGTTGGCTTAAGGATCCCTTAATACAGA 240	PR 02-OCT-2000; 2000US-237298P.	PR
Qy	181 GCAAATACCATGCAAAACAGCGCAGTTGGCTTAAGGATCCCTTAATACAGA 240	PR 02-OCT-2000; 2000US-237299P.	PR
Db	181 GCAAATACCATGCAAAACAGCGCAGTTGGCTTAAGGATCCCTTAATACAGA 240	PR 02-OCT-2000; 2000US-237295P.	PR
Qy	241 AAAGACACTCCAAAGCACTTCCGTTGACTCTGAGGACTCAAGCACAGAGAAAG 300	PR 02-OCT-2000; 2000US-237316P.	PR
Qy	241 AAAGACACTCCAAAGCACTTCCGTTGACTCTGAGGACTCAAGCACAGAGAAAG 300	PR 03-OCT-2000; 2000US-237425P.	PR
Db	241 AAAGACACTCCAAAGCACTTCCGTTGACTCTGAGGACTCAAGCACAGAGAAAG 300	PR 03-OCT-2000; 2000US-237598P.	PR
Qy	301 CCTTGTGATTCACATATTTGGACTCTGTGATTACATTTCAGTCATTAA 360	PR 03-OCT-2000; 2000US-237604P.	PR
Qy	301 CCTTGTGATTCACATATTTGGACTCTGTGATTACATTTCAGTCATTAA 360	PR 03-OCT-2000; 2000US-237605P.	PR
Db	301 CCTTGTGATTCACATATTTGGACTCTGTGATTACATTTCAGTCATTAA 360	PR 03-OCT-2000; 2000US-237608P.	PR
Qy	361 GGGGAAATTAACGTGACATAATT 383	PR 01-NOV-2000; 2000US-244867P.	PR
Db	361 GGGGAAATTAACGTGACATAATT 383	PR 01-NOV-2000; 2000US-245084P.	PR
		XX (AVAL-) AVALON PHARM.	XX
		XX Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;	XX
		XX Soppet DR, Weaver Z;	XX
		XX WPI: 2002-188264/24.	XX
		Screening for anti-neoplastic agent involves exposing cells to a	XX

fr - seq ID no : 1979

RESULT 1
ABL66669
ID ABL66669 standard; DNA; 550 BP.
XX
AC ABL66669;
XX
DT 15-MAY-2002 (first entry)
XX
DE Lung cancer related gene sequence SEQ ID NO:5006.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233131P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234003P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234502P.
PR 22-SEP-2000; 2000US-234567P.

continued →

ABL6669

- cont -

us-09-954-456-1979.rng

PR 25-SEP-2000; 2000US-234923P.
 PR 25-SEP-2000; 2000US-234924P.
 PR 25-SEP-2000; 2000US-235077P.
 PR 25-SEP-2000; 2000US-235134P.
 PR 25-SEP-2000; 2000US-235280P.
 PR 26-SEP-2000; 2000US-235637P.
 PR 27-SEP-2000; 2000US-235638P.
 PR 27-SEP-2000; 2000US-235711P.
 PR 27-SEP-2000; 2000US-235720P.
 PR 27-SEP-2000; 2000US-235840P.
 PR 27-SEP-2000; 2000US-235863P.
 PR 28-SEP-2000; 2000US-236028P.
 PR 21-SEP-2000; 2000US-236033P.
 PR 21-SEP-2000; 2000US-236034P.
 PR 28-SEP-2000; 2000US-236109P.
 PR 28-SEP-2000; 2000US-236111P.
 PR 29-SEP-2000; 2000US-236891P.
 PR 02-OCT-2000; 2000US-237172P.
 PR 02-OCT-2000; 2000US-237173P.
 PR 02-OCT-2000; 2000US-237278P.
 PR 02-OCT-2000; 2000US-237294P.
 PR 02-OCT-2000; 2000US-237316P.
 PR 03-OCT-2000; 2000US-237425P.
 PR 03-OCT-2000; 2000US-237598P.
 PR 03-OCT-2000; 2000US-237604P.
 PR 03-OCT-2000; 2000US-237606P.
 PR 01-NOV-2000; 2000US-24467P.
 PR 01-NOV-2000; 2000US-245084P.

(AVAL-) AVALON PHAR₄.

XX Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
 PI Sorpet DR, Weaver Z;
 XX DR WPI: 2002-188264/24.

PT Screening for anti-neoplastic agent involves exposing cells to a
 PT chemical agent to be tested for anti-neoplastic activity, and
 PT determining a change in expression of a gene of a signature gene set
 PS Claim 1; SEQ ID 5006; 44PP; English.

XX The present invention describes a method (M1) for screening for an
 CC anti-neoplastic agent. The method involves exposing cells to a chemical
 CC agent to be tested for anti-neoplastic activity, determining a change in
 CC expression of at least one gene (I) of a signature gene set, where (I)
 CC comprises a sequence (S) selected from 8447 sequences (given in ABL6664
 CC to ABI70110), or is at least 95% identical to (S), where a change in
 CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
 CC activity and can be used in gene therapy. M1 can be used for screening
 CC an anti-neoplastic agent, and can be used for producing a product which
 CC is the data collected with respect to the anti-neoplastic agent as a
 CC result of M1, and the data is sufficient to convey the chemical
 CC structure and/or properties of the agent. M1 can be used in the
 CC treatment of cancer, such as colon, breast, stomach, lung, thyroid,
 CC oesophageal, ovarian, kidney, prostate or pancreatic cancer, infiltrating ductal cancer,
 CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
 CC carcinoma, papillary carcinoma and Wilm's tumour.

SQ Sequence 550 BP; 131 A; 108 C; 117 G; 182 T; 12 other;

Query Match 97.8%; Score 538; DB 24; Length 550;
 Best Local Similarity 100.0%; Pred. No. 1.3e-144;
 Matches 549; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 TATGACTGAGCCGAGATTTTAAGAGATAAGGTAGTTAAATAGGTGTTAA 61
 Db 2 TATACTGAGCCGAGATTTTAAGAGATAAGGTAGTTAAATAGGTGTTAA 61
 Qy 62 ARAACTCTTGGAAATTCTAACAAATTGTTATTAAGCTTCAGAGT 121
 Db 62 ARAACTCTTGGAAATTCTAACAAATTGTTATTAAGCTTCAGAGT 121
 Qy 122 TGTGTTACATTCATCACCATCATTAAATGTTAAGTGTAGTTTATACACTTCAGAGT 181
 Db 122 TGTGTTACATTCATCACCATCATTAAATGTTAAGTGTAGTTTATACACTTCAGAGT 181
 Qy 182 CTATACAGCGGTTAACACCCCTCCCTGACTGTTAAATAGATGATTGCA 241
 Db 182 CTATACAGCGGTTAACACCCCTCCCTGACTGTTAAATAGATGATTGCA 241
 Qy 242 TAAACCACTGCTAGAAGACTTCCCACCTTGAGCTGGCTGGCAAGGCCGCAUTCCAC 301
 Db 242 TAAACCACTGCTAGAAGACTTCCCACCTTGAGCTGGCTGGCAAGGCCGCAUTCCAC 301
 Qy 302 ATCCCATACATGTTCCACTCCAGAAGCTCTGGGTTATCCAGNTTTATCN 361
 Db 302 ATCCCATACATGTTCCACTCCAGAAGCTCTGGGTTATCCAGNTTTATCN 361
 Qy 362 TGGACGTTCTCCNNTTCACCCCTGGGTTGGGTTGGGTTGGGTTTAANTCA 421
 Db 362 TGGACGTTCTCCNNTTCACCCCTGGGTTGGGTTGGGTTGGGTTGGGTTTAANTCA 421
 Qy 422 GGAAGTTTCGGGATCAAGGGGTCNGACNNTTAAACCGGGCGAGTAGCTG 481
 Db 422 GGAAGTTTCGGGATCAAGGGGTCNGACNNTTAAACCGGGCGAGTAGCTG 481
 Qy 482 CNNTTTTGTGTTGGTGTAGGTTGGTGTACAGGNACCCANTGCCNNTAGTGTG 541
 Db 482 CNNTTTTGTGTTGGTGTAGGTTGGTGTACAGGNACCCANTGCCNNTAGTGTG 541
 Qy 542 GTAGTGT 550
 Db 542 GGTTGT 550

Query Match 97.0%; Score 356; DB 10; Length 405;
 Matches 367; Conservative 99.7%; Pread. No. 7.1E-89;
 Best Local Similarity 99.7%; DB 10; Length 405;
 Gaps 1;
 Mismatches 0; Indels 0;
 Query Match 1 TTAGAGAACATTACATTAACATTGCACTAAAGAACATTAATTTCGCTCGAAGTCAA
 DB 1 AAAATGAACTCCAAAGCATTTGCACATTTAACATTTACGTTCCACATTACGAGATGCTC
 QY 61 AAAATGAACTCCAAAGCATTTGCACATTTAACATTTACGTTCCACATTACGAGATGCTC 119
 DB 65 AAAATGAACTCCAAAGCATTTGCACATTTAACATTTACGTTCCACATTACGAGATGCTC
 QY 120 TAACTCAGTCATGTCATTAACATTGCACTAAAGAACATTAATTTCGCTCGAAGTCAA 179
 DB 125 TAACTCAGTCATGTCATTAACATTGCACTAAAGAACATTAATTTCGCTCGAAGTCAA 184
 QY 180 TTCTTGACATGTCATTAACATTGCACTAAACACTTCCTCCCTCCAG 239
 DB 185 TTCTTGACATGTCATTAACATTGCACTAAACACTTCCTCCCTCCAG 244
 QY 240 TAAATACCTTGACATCACAATGGAAATGAACTGAGCCAGATG 299
 DB 245 TAAATACCTTGACATCACAATGGAAATGAACTGAGCCAGATG 304
 QY 300 CACTACAGGATTAAGGATTCGAACTGAACTGAACTGAACTGAACTG 359
 DB 305 CACTACAGGATTAAGGATTCGAACTGAACTGAACTGAACTGAACTG 364
 QY 360 ATTGAAATC 367
 DB 365 ATTGAAATC 372

ORIGIN
 BASE COUNT 122 a 77 c 72 g 134 t
 Library constructed by life technologies.
 Site:2; (Not); Cloned undirected. Primer: oligo dT.
 /Lab-host="DHL0B"/
 /Issue-type="Two pooled squamous cell carcinomas"
 /Clone-ID="NCI-CGAP-Lu28"
 /Clone="IMAGE:2819062"
 /db_xref="Taxon:9066"
 /organism="Homo sapiens"
 SOURCE 1. 405
 FEATURES location/quality filters
 Seg primer: -40bp from gblock
 High quality sequence stop: 404.
 www-bio-lulu1.nch.gov/bibp/image.htm
 found through the I.M.A.G.E. Consortium University.
 Clone distribution: NCI-CGAP clone distribution information can be
 genome sequencing center
 I.M.A.G.E. Consortium DNA sequencing by: Washington University.
 Technologies, Inc. CNA library arrayed by: Chiseta Preparations, Inc.
 Embret-Buck, M.D., Ph.D., CNA Library Preparation: Life
 tissue procurement: Chris Moskalauk, M.D., Ph.D., Michael R.

COMMENT
 JOURNAL
 TITLE
 AUTHORS NCI-CGAP Index
 REFERENCE NCI-CGAP http://www.ncbi.nlm.nih.gov/cgap.
 Mammalia: Butcher; Primates; Catarrhini; Hominidae; Homo.
 Bivalvia: Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;
 ORGANISM Homo sapiens
 SOURCE Human
 VERSION AW275150
 ACCESSION AW275150.1 GI:6662180
 DEPICTION 405 bp mRNA Linear EST
 DEFINITION mRNA sequence.
 LOCUS AW275150
 RESULT 2 AW275150
 DEPICTION 405 bp mRNA Linear EST 03-JAN-2000

RESULTS	AIS21564	LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM
3	AIS21564			AI521564	EST	MtRNA Segments.	Human	Homo sapiens
				AI521564.1	GI:4435699			Bukaryotes; Metazoa; Chordata; Crustacea; Vertebrata; Buteleostomi;
								Mammalia; Buthephila; Primates; Catarrhini; Hominidae; Homo.
								National Cancer Institute, NIH, Gov't/Catalog.
								Tumor Gene Index
								Genome Anatomy Project (CGAP)

ABK64299	ID	ABK64299 standard; DNA; 367 BP.
AC	XX	
DE	XX	Human benign prostate hyperplasia gene #194.
KM	XX	Human benign prostate hyperplasia; BPH; prostate cancer; gene; ds.
OS	XX	Homo sapiens.
PN	XX	W0200212440-A2.
PD	XX	14-FEB-2002.
PP	XX	07-AUG-2001; 2001W0-US24708.
PR	XX	07-AUG-2000; 2000US-223323P.
PA	XX	(GENE-) GENE LOGIC INC.
PB	XX	(NISB) JAPAN TOBACCO INC.
PI	XX	Munegi WE, Kulkarni P, Getzenberg RH, Waga I, Yamamoto J;
PT	XX	MP1; 2002-257476/30.
XX	XX	detecting drugs for and diagnosing benign prostate hyperplasia, by determining expression levels of one or more genes in prostate cells from

for SEQ ID N^o, 2032

AB66722
ID ABL66722 standard; DNA; 367 BP.
XX AC
XX DT
15-MAY-2002 (first entry)

DE Lung cancer related gene sequence SBQ ID NO:5059.

KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antrumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilms tumour; adenocarcinoma;
KW gene; ds.

OS Homo sapiens.

PN WO20019629-R2.

XX PD 13-DEC-2001.

XX PD 30-MAY-2001; 2001WO-US10838.

XX PR 05-JUN-2000; 2000US-209473P.

PR 18-SEP-2000; 2000US-233133P.

PR 18-SEP-2000; 2000US-23317P.

PR 20-SEP-2000; 2000US-234009P.

PR 20-SEP-2000; 2000US-234034P.

PR 22-SEP-2000; 2000US-234052P.

PR 22-SEP-2000; 2000US-234059P.

PR 22-SEP-2000; 2000US-234567P.

PR 25-SEP-2000; 2000US-234923P.

PR 25-SEP-2000; 2000US-235077P.

PR 25-SEP-2000; 2000US-235134P.

PR 25-SEP-2000; 2000US-235280P.

PR 26-SEP-2000; 2000US-235638P.

PR 27-SEP-2000; 2000US-235711P.

PR 27-SEP-2000; 2000US-235720P.

PR 27-SEP-2000; 2000US-235840P.

PR 27-SEP-2000; 2000US-235863P.

PR 28-SEP-2000; 2000US-236028P.

PR 28-SEP-2000; 2000US-236032P.

PR 28-SEP-2000; 2000US-236034P.

PR 28-SEP-2000; 2000US-236109P.

PR 28-SEP-2000; 2000US-236111P.

PR 29-SEP-2000; 2000US-236819P.

PR 02-OCT-2000; 2000US-237172P.

PR 02-OCT-2000; 2000US-237173P.

CC comprises a sequence (S) selected from 8447 sequences (given in AB661664 to AB670110), or is at least 95% identical to (S), where a change in expression is indicative of anti-neoplastic activity. (I) has cytostatic activity and can be used in gene therapy. M1 can be used for screening an anti-neoplastic agent, and can be used for producing a product which is the data collected with respect to the anti-neoplastic agent as a result of M1, and the data is sufficient to convey the chemical structure and/or properties of the agent. M1 can be used in the treatment of cancer such as, colon, breast, stomach, lung, thyroid, oesophageal, ovarian, kidney, prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell cancer, infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilms' tumour.

XX SQ Sequence 367 BP; 111 A; 69 C; 67 G; 120 T; 0 other;

Query Match 100.0%; Score 367; DB 24; Length 367;
Best Local Similarity 100.0%; Pred. No. 2.7e-97; Mismatches 0; Indels 0; Gaps 0;
Matches 367; Conservative 0; Gaps 0;

Qy 1 TTTGAGGRATGGCAATTATTCATAAAAGAAGCATTAATTTGCTACAGTGGAA 60
Db 1 TTGGAGGATGAGCAATTATTCATAAAAGAAGCATTAATTTGCTACAGTGGAA 60
Qy 61 AAATGAACTCAGAGTGCTACATTGACTGTATGCCATTATCTCTGACGAGTCT 120
Db 61 AAATGAACTCAGAGTGCTACATTGACTGTATGCCATTATCTCTGACGAGTCT 120
Qy 121 TATCTCAGTGTCACTCACAAATATGATGAAATACACCGTTGGTGT 180
Db 121 TATCTCAGTGTCACTCACAAATATGATGAAATACACCGTTGGTGT 180
Qy 181 TGCAGACAGTGTAGATTAGGGAGACTCTAACACCCTCTCTTTCCTCCAGT 240
Db 181 TGCAGACAGTGTAGATTAGGGAGACTCTAACACCCTCTCTTTCCTCCAGT 240
Qy 241 AAATCTTGTGACTTGTGACCCACCATATTGAAATGACAGTGTGCCCCAGTG 300
Db 241 AAATCTTGTGACTTGTGACCCACCATATTGAAATGACAGTGTGCCCCAGTG 300
PT chemical agent involves exposing cells to a
determining a change in expression of a gene of a signature gene set -

PS Claim 1; SEQ ID 5059; 44pp; English.

PA (AVAL-) AVALON PHARM.
PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
PI Soppet DR, Weaver Z;
XX WPI; 2002-188264/24.

PT Screening for anti-neoplastic agent involves exposing cells to a
determining a change in expression of a gene of a signature gene set -

PS Claim 1; SEQ ID 5059; 44pp; English.

CC The present invention describes a method (M1) for screening for an
anti-neoplastic agent. The method involves exposing cells to a chemical
agent to be tested for anti-neoplastic activity, determining a change in
expression of at least one gene (I) of a signature gene set, where (I)

us-09-954-4

May 27 08:34:37 2003

us-09-954-4

PT chemical agent to be tested for anti-neoplastic activity, and
determining a change in expression of a gene of a signature gene set -

PS Claim 1; SEQ ID 5059; 44pp; English.

CC The present invention describes a method (M1) for screening for an
anti-neoplastic agent. The method involves exposing cells to a chemical
agent to be tested for anti-neoplastic activity, determining a change in
expression of at least one gene (I) of a signature gene set, where (I)

CC

CC